# Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

> **NCT02349633** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 65 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** PF-06747775
- **DRUG:** Palbociclib
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT02349633
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-14
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-05-28
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** The study was ended for strategic reasons and changes in the external environment.

The safety profile and risk benefit ratio for PF-0674775 remained unchanged.
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349633, "Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02349633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*